Diaz-Montero and colleagues [30] initially suggested that human MDSC levels correlate with disease stage and preliminary data from an on-going clinical study in our laboratory suggests that MDSC detection in peripheral blood using definitive biomarkers for CD33+ and CD11b+ subsets can distinguish cancer patients from healthy individuals (Figure 10). The gene discussed is CD33; the disease is cancer.